Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Phase 3 Obesity Program On Track For Q3 2026

Loading news article.

Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Phase 3 Obesity Program On Track For Q3 2026 | WAPE

Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Phase 3 Obesity Program On Track For Q3 2026

Article summary

Related companies

Comments —